Position in CAI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$16,963,605
+$9,626,727 QoQ
Shares Held
951,942
+132.0% QoQ
Ownership
0.337%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#32
of 246 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in CAI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GOLDMAN SACHS GROUP INC holds $13,040,376,854 across 359 Biotechnology names. CAI ranks #126 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,481,761 | $1,232,765,138 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,163,191 | $725,296,113 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
18,556,458 | $656,713,046 | |
| 4 | TECH |
BIO-TECHNE Corp
|
7,343,324 | $518,805,838 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
2,133,101 | $399,487,154 | |
| 6 | MRNA |
Moderna, Inc.
|
4,671,950 | $327,176,656 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
9,980,620 | $311,994,180 | |
| 8 | INCY |
Incyte Corp
|
2,305,782 | $261,383,446 |
All Filings in CAI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,963,605 | 951,942 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $7,336,878 | 410,340 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $8,536,822 | 282,209 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $4,869,800 | 182,253 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||